UBS Group’s Lixte Biotechnology LIXT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01K | Sell |
1,112
-7,179
| -87% | -$6.5K | ﹤0.01% | 8363 |
|
|
2025
Q1 | $10K | Buy |
8,291
+6,335
| +324% | +$7.67K | ﹤0.01% | 7345 |
|
|
2024
Q4 | $3.97K | Buy |
1,956
+1,589
| +433% | +$3.23K | ﹤0.01% | 7564 |
|
|
2024
Q3 | $686 | Buy |
367
+22
| +6% | +$41 | ﹤0.01% | 7628 |
|
|
2024
Q2 | $818 | Buy |
+345
| New | +$818 | ﹤0.01% | 7602 |
|
|
2024
Q1 | – | Sell |
-3
| Closed | -$7 | – | 8417 |
|
|
2023
Q4 | $7 | Buy |
+3
| New | +$7 | ﹤0.01% | 7922 |
|
|
2023
Q3 | – | Sell |
-101
| Closed | -$594 | – | 8519 |
|
|
2023
Q2 | $594 | Sell |
101
-971
| -91% | -$5.71K | ﹤0.01% | 7084 |
|
|
2023
Q1 | $8.87K | Buy |
1,072
+124
| +13% | +$1.03K | ﹤0.01% | 6593 |
|
|
2022
Q4 | $4.83K | Buy |
948
+231
| +32% | +$1.18K | ﹤0.01% | 8076 |
|
|
2022
Q3 | $4K | Buy |
717
+273
| +61% | +$1.52K | ﹤0.01% | 8266 |
|
|
2022
Q2 | $3K | Sell |
444
-288
| -39% | -$1.95K | ﹤0.01% | 8292 |
|
|
2022
Q1 | $9K | Sell |
732
-19
| -3% | -$234 | ﹤0.01% | 7500 |
|
|
2021
Q4 | $9K | Buy |
751
+347
| +86% | +$4.16K | ﹤0.01% | 7790 |
|
|
2021
Q3 | $8K | Buy |
404
+213
| +112% | +$4.22K | ﹤0.01% | 7056 |
|
|
2021
Q2 | $6K | Buy |
+191
| New | +$6K | ﹤0.01% | 7342 |
|
|
2021
Q1 | – | Sell |
-168
| Closed | -$5K | – | 8092 |
|
|
2020
Q4 | $5K | Buy |
+168
| New | +$5K | ﹤0.01% | 6802 |
|